EGFR and neoplasm: Triazole-substituted quinazoline derivatives have been synthesized for their epidermal growth factor receptor (EGFR) tyrosine kinase activity and demonstrated moderate activity in tumor cell lines (HCT116, MCF-7 and PC-3) [15].